GSK will supply over 30 million doses of flu vaccines to U.S. this season
PHILADELPHIA The influenza virus vaccines Fluarix and FluLaval from GlaxoSmithKline will have a combined total of 30 million to 35 million doses supplied to the U.S. markets for the 2007-08 influenza season.
The vaccines will be delivered in phased approach for the rest of September and all of October with completion occurring at the end of October. “Providing an ample and steadily growing supply of flu vaccine has been a priority for GlaxoSmithKline since entering the U.S. market in 2004,” said David Pernock, senior vice president of GSK. “Over the years, GSK has significantly increased its influenza vaccine manufacturing capacity, and we have taken steps to improve the way this product is distributed to those who need it.”
Last year, the company sent about 25 million doses of the drugs for flu season.
Roche to sue Teva over patent of Boniva
BASEL, Switzerland Swiss pharmaceutical company Roche Holding has filed suit against generic pharmaceutical maker Teva over Roche’s patented osteoporosis treatment, the company said Tuesday.
Roche filed a complaint at a New Jersey district court to prevent Teva from selling their generic version of Boniva, the company’s spokeswoman said.
Sales of Boniva for the first six months of the year totaled $314 million. Recently, Roche’s rival Novartis filed for an injunction against the generic pharmaceutical maker to halt the creation and production of its Famvir herpes treatment. Novartis was denied the injunction but was granted one by the U.S. District Court of Appeals a few days later.
King Pharma announces intention to fight Actavis’ generic Avinza
BRISTOL, Tenn. King Pharmaceuticals has recently learned that Actavis has filed paperwork with the Food and Drug Administration to make a generic version of their pain medication Avinza (morphine sulfate).
King “intends to vigorously enforce the patent on Avinza” by starting legal procedures that will most likely ending up with the two companies meeting in federal court. King spokesman James Green said, “The business of generic manufacturers is to challenge as many patents as possible, hoping to win a few.”
At the beginning of the year King acquired all the rights to Avinza from Ligand Pharmaceuticals and has seen revenues of $9 million and $35 million in the first and second quarters of 2007.
Avinza’s patent does not end until Nov. 25, 2017.